Servant of God, persuer of the truth, Patriot, dog breeder. WWG1WGA (Please don't follow me if you are looking for a romantic hookup)
IVERMECTIN:Broad-Spectrum Anticancer Potential
(Open picture to see all)
Documented tumor suppression and inhibitory effects have been observed across multiple oncological areas (Reference: PMC7505114):
➡️Gastrointestinal: Colorectal and Pancreatic cancers.
➡️Hormonal: Breast, Ovarian, and Prostate cancers.
➡️Respiratory: Non-small cell lung cancer (NSCLC).
➡️Neurological: High-grade Glioblastomas (Brain Cancer).
➡️Hematological: Leukemia and Lymphoma.
- STAT3 signaling inhibition.
A comprehensive clinical review suggests a significant paradigm shift in modern oncology.
While widely recognized for its safety profile over four decades, Ivermectin is now demonstrating potent effects across an extensive range of malignant cell lines. This is no longer just observational data; it is molecular science.
Core Molecular Mechanisms:
Unlike single-target therapies, Ivermectin appears to exert its anticancer effects through a sophisticated, multi-front attack on the disease:
1️⃣ Transcriptional Inhibition: It effectively targets and suppresses key signaling pathways, including Wnt/β-catenin, STAT3, and mTOR, which are frequently overexpressed in aggressive, treatment-resistant tumors.
2️⃣ Induction of Immunogenic Cell Death: By promoting ROS (Reactive Oxygen Species) stress and mitochondrial dysfunction, Ivermectin triggers apoptosis (programmed cell death) while simultaneously enhancing the host's natural antitumor immune response.
3️⃣ Targeting Cancer Stem Cells (CSCs): Compelling evidence suggests Ivermectin may inhibit the "roots" of tumor recurrence, potentially addressing the critical challenge of metastasis and therapy resistance.
The Clinical Gap: Despite these compelling molecular findings, large-scale clinical trials for these off-patent applications remain critically underfunded. 💸
